# EDGAR Filing Document

**Accession Number:** 0000811641
**File Stem:** 0001213900-25-062192
**Filing Date:** 2025-7
**Character Count:** 16618
**Document Hash:** 8605eed3870bddc6e80e3cd63ade2426
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-062192.hdr.sgml**: 20250709

**ACCESSION NUMBER**: 0001213900-25-062192

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20250709

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250709

**DATE AS OF CHANGE**: 20250709

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** IMMUCELL CORP /DE/
- **CENTRAL INDEX KEY:** 0000811641
- **STANDARD INDUSTRIAL CLASSIFICATION:** IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 010382980
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-12934
- **FILM NUMBER:** 251112300

**BUSINESS ADDRESS:**
- **STREET 1:** 56 EVERGREEN DR
- **CITY:** PORTLAND
- **STATE:** ME
- **ZIP:** 04103
- **BUSINESS PHONE:** 2078782770

**MAIL ADDRESS:**
- **STREET 1:** 56 EVERGREEN DRIVE
- **CITY:** PORTLAND
- **STATE:** ME
- **ZIP:** 04103

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported) <u>July 9, 2025</u>

---

| |
|:---|
| **ImmuCell Corporation** |
| (Exact name of registrant as specified in its charter) |

---

<u>DE</u> <u>001-12934</u> <u>01-0382980</u> <br> (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

<u>56 Evergreen Drive Portland, Maine</u> <u>04103</u> <br> (Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code <u>207-878-2770</u>

  <br> (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K ﬁling is intended to simultaneously satisfy the ﬁling obligation of the Registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | |
|:---|:---|
| **Title of each class** | **Name of each exchange on which registered** |
| Common Stock, $0.10 par value per share ICCC | The NASDAQ Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 2.02. Results of Operations and Financial Condition**

On July 9, 2025 ImmuCell Corporation (the "Company") issued a press release announcing its preliminary, unaudited product sales for the quarter ended June 30, 2025. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

**Item 9.01. Financial Statements and Exhibits.**

(d) <u>Exhibits</u>.

The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:

99.1 [Press Release of ImmuCell Corporation dated July 9, 2025.](ea024834701ex99-1_immucell.htm) <br>104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **IMMUCELL CORPORATION** | **IMMUCELL CORPORATION** |
| Date: July 9, 2025 | By: | */s/* Michael F. Brigham |
|  |  | Michael F. Brigham |
|  |  | President and Chief Executive Officer |
|  | By: | /s/ Timothy C. Fiori |
|  |  | Chief Financial Officer |

---

**Exhibit Index**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | [Press Release of ImmuCell Corporation dated July 9, 2025.](ea024834701ex99-1_immucell.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

## Exhibit 99.1

**Exhibit 99.1**

**ImmuCell**

**ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 of 2025**

***<u>For Immediate Release</u>***

**PORTLAND, Maine – July 9, 2025 – ImmuCell Corporation (Nasdaq: ICCC)** ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the second quarter of 2025.

Since the first quarter of 2020, the Company has been providing a preliminary look at its unaudited top line results soon after the close of the quarter. The Company expects to continue providing this prompt, preliminary report on product sales until further notice going forward.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Preliminary, Unaudited Total Sales Results:** | **Preliminary, Unaudited Total Sales Results:** | **Preliminary, Unaudited Total Sales Results:** | **Preliminary, Unaudited Total Sales Results:** | **Preliminary, Unaudited Total Sales Results:** |
|  | **2025** | **2024** | **$ Increase** | **% Increase** |
| During the Three-Month Periods Ended June 30, | $6.4 million | $5.5 million | $972000 | 18% |
| During the Six-Month Periods Ended June 30, | $14.5 million | $12.7 million | $1.8 million | 14% |
| During the Nine-Month Periods Ended June 30, | $22.3 million | $17.8 million | $4.4 million | 25% |
| During the Twelve-Month Periods Ended June 30, | $28.3 million | $23.2 million | $5.1 million | 22% |

---

As displayed in the table above, product sales increased by 18%, 14%, 25% and 22% during the three-month, six-month, nine-month and twelve-month periods ended June 30, 2025 in comparison to the same periods ended June 30, 2024, respectively.

With increased production output, the Company has now met current customer demand and reduced the order backlog to under $100,000 as of June 30, 2025, which largely reflects normal timing differences between order dates and shipment dates and is down from approximately $3.4 million as of May 6, 2025. The recent sales pace reflects, in part, the replenishment of the distribution pipeline following an extended period during which product supply fell short of demand. During that time, distributors operated with minimal to no buffer inventory stock. Now that distribution inventories have been rebuilt, the Company is back to shipping within one week of order receipt. As a result, the Company's commercial team has transitioned its focus from managing product allocations to pursuing new business and re-engaging customers affected during the period of short supply.

1 of 3

"Our investments to increase production capacity to over $30 million per year were challenging and did take longer than we had planned. We are now evaluating incremental liquid processing and freeze-drying investments to increase capacity by an additional 33% to approximately $40 million or more to capitalize on potential demand growth in the North American dairy and beef markets," commented Michael F. Brigham, President and CEO of ImmuCell. "Although buffer stock replenishment and backlog depletion may result in one-time lifts in volume, our teams remain focused on the sustainable, long-term growth of the **First Defense**<sup>®</sup> product line."

As previously disclosed by the Company, the Company is initiating Investigational Product use of **Re-Tain**<sup>®</sup> to test market acceptance of the product over the last six months of 2025. This exciting initiative reflects the innovative nature of this novel product and its safety profile and allows us to utilize available inventory before shelf-life expiration to collect critical product performance data. This opportunity is not, however, expected to generate significant revenue or profit. The Company made its Non-Administrative New Animal Drug Application (NADA) submission, that included its fourth submission of the CMC Technical Section, together with the minor technical sections covering All Other Information and Product Labeling during early January of 2025. Clearing inspectional observations at the facilities of the Company's contract manufacturer is still the critical path constraint to NADA approval.

**<u>Conference Call:</u>**

The Company is planning to host a conference call on Friday, August 15, 2025, at 9:00 AM ET to discuss the unaudited financial results for the quarter ended June 30, 2025. Interested parties can access the conference call by dialing (844) 855-9502 (toll free) or (412) 317-5499 (international) at 9:00 AM ET. A teleconference replay of the call will be available until August 22, 2025, at (877) 344-7529 (toll free) or (412) 317-0088 (international), utilizing replay access code #5659118. Investors are encouraged to review the Company's Corporate Presentation slide deck that provides an overview of the Company's business and is available under the "Investors" tab of the Company's website at www.immucell.com, or by request to the Company. An updated version of the slide deck is expected to be made available after the market closes on Thursday, August 14, 2025.

**<u>About ImmuCell:</u>**

ImmuCell Corporation's (**Nasdaq: ICCC**) purpose is to create scientifically proven and practical products that improve the health and productivity of dairy and beef cattle. ImmuCell manufactures and markets **First Defense**<sup>®</sup>, providing **Immediate Immunity**™ to newborn dairy and beef calves, and is in the late stages of developing **Re-Tain<sup>®</sup>**, a novel treatment for subclinical mastitis in dairy cows without FDA-required milk discard or pre-slaughter withdrawal label restrictions that provides an alternative to traditional antibiotics. Press releases and other information about the Company are available at: http://www.immucell.com.

2 of 3

**<u>Cautionary Note Regarding Forward-Looking Statements (Safe Harbor Statement):</u>**

This Press Release and the statements to be made in the related conference call referenced herein contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts and will often include words such as "expects", "may", "anticipates", "aims", "intends", "would", "could", "should", "will", "plans", "believes", "estimates", "targets", "projects", "forecasts", "seeks" and similar words and expressions. Such statements include, but are not limited to, any forward-looking statements relating to: our plans, goals and strategies for our business; projections of future financial or operational performance; the timing and outcome of pending or anticipated applications for regulatory approvals and pending or anticipated regulatory inspections of our facilities and those of our contract manufacturers; future demand for our products; future adoption of **Re-Tain<sup>®</sup>** by dairy producers; growth in acceptance of our **First Defense<sup>®</sup>** product line by dairy and beef producers; the impact of the global supply-chain disruptions on our ability to obtain, in a timely and cost-effective fashion, all the supplies and components we need to produce our products; the impact of inflation and rising interest rates on our operating expenses and financial results; the scope and timing of ongoing and future product development work and commercialization of our products; future costs of product development efforts; future incidence rates of subclinical mastitis and producers' level of interest in treating subclinical mastitis; the expected efficacy of new products; estimates about the market size for our products; future market share of and revenue generated by current products and products still in development; our ability to increase production output and reduce costs of goods sold per unit; the adequacy of our own manufacturing facilities or those of third parties with which we have contractual relationships to meet demand for our products on a timely basis; the impacts of backlogs on customer relationships; the efficacy of our contamination remediation efforts; whether or not we will experience future contamination events; the anticipated costs of (or time to complete) planned expansions of our manufacturing facilities and the adequacy of our funds available for these projects; the robustness of our manufacturing processes to meet future demand and related technical issues; estimates about our future production capacity, efficiency and yield; the salability of products currently held in inventory pending regulatory approval; future regulatory requirements relating to our products; future expense ratios and margins; the future consequences and effectiveness of our investments in our business; anticipated changes in our manufacturing capabilities and efficiencies; our future effectiveness in competing against competitors within both our existing and our anticipated product markets; and any other statements that are not historical facts. These statements are intended to provide management's current expectations of future events as of the date of this earnings release, are based on management's estimates, projections, beliefs and assumptions as of the date hereof; and are not guarantees of future performance. Such statements involve known and unknown risks and uncertainties that may cause the Company's actual results, financial or operational performance or achievements to be materially different from those expressed or implied by these forward-looking statements, including, but not limited to, those risks and uncertainties relating to: difficulties or delays in development, testing, regulatory approval, production and marketing of our products (including the **First Defense<sup>®</sup>** product line and **Re-Tain<sup>®</sup>**), competition within our anticipated product markets, customer acceptance of our new and existing products, product performance, alignment between our manufacturing resources and product demand (including the consequences of backlogs), uncertainty associated with the timing and volume of customer orders as we come out of a prolonged backlog, adverse impacts of supply chain disruptions on our operations and customer and supplier relationships, commercial and operational risks relating to our current and planned expansion of production capacity, and other risks and uncertainties detailed from time to time in filings we make with the Securities and Exchange Commission (SEC), including our Quarterly Reports on Form 10-Q, our Annual Reports on Form 10-K and our Current Reports on Form 8-K. Such statements involve risks and uncertainties and are based on our current expectations, but actual results may differ materially due to various factors. In addition, there can be no assurance that future risks, uncertainties or developments affecting us will be those that we anticipate. We undertake no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

**Contacts:** 

Michael F. Brigham, President and CEO

Timothy C. Fiori, CFO

ImmuCell Corporation

(207) 878-2770

Joe Diaz, Robert Blum and Joe Dorame

Lytham Partners, LLC

(602) 889-9700

iccc@lythampartners.com

3 of 3